International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Beyer-Westendorf, Jan; Camm, A John; Fox, Keith A A; Le Heuzey, Jean-Yves; Haas, Sylvia; Turpie, Alexander G G; Virdone, Saverio; Kakkar, Ajay K

Beyer-Westendorf, Jan; Camm, A John; Fox, Keith A A; Le Heuzey, Jean-Yves; Haas, Sylvia; Turpie, Alexander G G; Virdone, Saverio; Kakkar, Ajay K.

Afiliación

Beyer-Westendorf J; 1Thrombosis Research Unit, Department of Medicine I, Division Haematology, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany.
Camm AJ; 2Kings Thrombosis Service, Department of Haematology, Kings College London, London, UK.
Fox KAA; 3Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, St. George's University of London, London, UK.
Le Heuzey JY; 4Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
Haas S; 5Georges Pompidou Hospital, René Descartes University, Paris, France.
Turpie AGG; 6Formerly Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Virdone S; 7McMaster University, Hamilton, Canada.
Kakkar AK; 8Thrombosis Research Institute, London, UK.

Thromb J ; 17: 7, 2019.

Article en En | MEDLINE | ID: mdl-31169831

Palabras clave

Anticoagulant; Antithrombotic; Atrial fibrillation; Outcomes; Registry; Rivaroxaban

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Thromb J Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google